Literature DB >> 27139483

Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Mamun-Ur Rashid1, Staffan Rosenborg2, Georgios Panagiotidis2, Johan Holm2, Karin Söderberg Löfdal2, Andrej Weintraub3, Carl Erik Nord1.   

Abstract

Solithromycin is a new fluoroketolide. The purpose of the present study was to investigate the effect of orally administered solithromycin on the human oropharyngeal and intestinal microbiota. Thirteen healthy volunteers (median age, 27.3 years) received oral solithromycin at 800 mg on day 1 followed by 400 mg daily on days 2 to 7. Fecal and saliva samples were collected at baseline and on days 2, 5, 7, 9, 14, and 21 for pharmacokinetic and microbiological analyses. Plasma samples were collected predose on days 2, 5, and 7 as proof of exposure, and solithromycin concentration ranges were 21.9 to 258 ng/ml, 18.0 to 386 ng/ml, and 16.9 to 417 ng/ml, respectively. The solithromycin concentrations in feces were 15.8 to 65.4 mg/kg, 24.5 to 82.7 mg/kg, 21.4 to 82.7 mg/kg, 12.1 to 72.4 mg/kg, 0.2 to 25.6 mg/kg, and 0 to 0.5 mg/kg on days 2, 5, 7, 9, 14, and 21, respectively. The numbers of enterobacteria and enterococci decreased and were normalized on day 14. The numbers of lactobacilli and bifidobacteria decreased from day 2 to day 14 and were normalized on day 21. The clostridia decreased on days 2, 7, and 14 and were normalized on day 21. No Clostridium difficile strains or toxins were detected during the study period. The number of Bacteroides strains was not significantly changed. The solithromycin concentrations in saliva were 0 to 1.2 mg/liter, 0 to 0.5 mg/liter, 0 to 0.5 mg/liter, and 0 to 0.1 mg/liter on days 2, 5, 7, and 9, respectively. The numbers of streptococci decreased on day 2 and were normalized on day 5. The numbers of lactobacilli, prevotellae, fusobacteria, and leptotrichiae decreased from day 2 and were normalized on day 21.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27139483      PMCID: PMC4914664          DOI: 10.1128/AAC.00461-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora.

Authors:  C Edlund; G Alván; L Barkholt; F Vacheron; C E Nord
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

2.  Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora.

Authors:  G Beyer; M Hiemer-Bau; S Ziege; C Edlund; H Lode; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-07       Impact factor: 3.267

3.  A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.

Authors:  Edward W Hook; Matthew Golden; Brian D Jamieson; Paula B Dixon; Hanne S Harbison; Sylvan Lowens; Prabhavathi Fernandes
Journal:  Clin Infect Dis       Date:  2015-06-18       Impact factor: 9.079

4.  In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?

Authors:  Daniel Golparian; Prabhavathi Fernandes; Makoto Ohnishi; Jörgen S Jensen; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

5.  OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.

Authors:  Thomas J Louie; Judy Emery; Walter Krulicki; Brendan Byrne; Manuel Mah
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Effect of erythromycin and clindamycin on the indigenous human anaerobic flora and new colonization of the gastrointestinal tract.

Authors:  A Heimdahl; C E Nord
Journal:  Eur J Clin Microbiol       Date:  1982-02       Impact factor: 3.267

7.  Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora.

Authors:  C Edlund; G Beyer; M Hiemer-Bau; S Ziege; H Lode; C E Nord
Journal:  Scand J Infect Dis       Date:  2000

8.  Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia.

Authors:  David Oldach; Kay Clark; Jennifer Schranz; Anita Das; J Carl Craft; Drusilla Scott; Brian D Jamieson; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

Review 9.  The role of solithromycin in the management of bacterial community-acquired pneumonia.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Expert Rev Anti Infect Ther       Date:  2016-02-05       Impact factor: 5.091

10.  Impact of dirithromycin on the normal oral and intestinal microflora.

Authors:  S A Eckernäs; A Grahnén; C E Nord
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-08       Impact factor: 3.267

View more
  2 in total

Review 1.  Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.

Authors:  George G Zhanel; Erika Hartel; Heather Adam; Sheryl Zelenitsky; Michael A Zhanel; Alyssa Golden; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Andrew J Walkty; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2016-12       Impact factor: 9.546

Review 2.  Leptotrichia species in human infections II.

Authors:  Emenike R K Eribe; Ingar Olsen
Journal:  J Oral Microbiol       Date:  2017-09-15       Impact factor: 5.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.